Managing mild autonomous cortisol secretion (MACS): evaluating the role of medical treatment

Category	Detail
Condition	Mild Autonomous Cortisol Secretion (MACS)
Key Mechanisms	Characterized by cortisol excess, particularly during the nocturnal period, leading to various comorbidities.
Target Population	Patients with adrenal incidentaloma and post-dexamethasone serum cortisol >50nmol/L without overt Cushing’s syndrome.
Care Setting	Endocrinology and metabolic health management.

MACS is associated with increased risk of diabetes, hypertension, dyslipidemia, and cardiovascular events.
Surgical intervention (adrenalectomy) may improve metabolic outcomes in patients with multiple comorbidities.
Metyrapone and Mifepristone have shown potential in managing MACS by targeting cortisol excess.
Current management strategies focus on optimizing control of associated comorbidities.
Larger randomized controlled trials are needed to confirm the efficacy and safety of medical treatments.

Consider surgical intervention in patients with progressive and difficult-to-treat cortisol-related comorbidities.

Systematic evaluation and screening for potential complications in affected individuals.

Increased risk of cardiovascular events, mortality, frailty, and fragility fractures.

Patients with MACS exhibiting elevated evening serum cortisol and blunted circadian rhythm.

Metyrapone and Mifepristone have shown improvements in metabolic parameters and cortisol control.

Individualized decision-making regarding surgical intervention is essential.
Monitor for comorbidities associated with cortisol excess.
Consider medical therapy as a potential option for patients not suitable for surgery.

Clinical Scorecard: Evaluating Medical Interventions in the Management of Mild Autonomous Cortisol Secretion (MACS)